Whipple’s Disease Market Share

Whipple’s Disease Market Overview

Whipple’s Disease Market Size was valued at USD 0.47 Billion in 2023. The Global Whipple’s Disease industry is projected to grow from USD 0.49 Billion in 2024 to USD 0.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.98% during the forecast period (2024 - 2032).

Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially,  the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes. 

Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms. The prevalence is one in one million people. The prevalence of this diseases is more in men than women.

Ongoing research and clinical trial to find effective cure drive the growth of whipple’s disease market. Advancement in medical technology and increasing awareness about this disease boost the whipple’s disease market growth.

Key Players in the Whipple’s Disease Market      

Some of the key players in whipple’s disease market: 

• AbbVie Inc. (US)


• Allergan (Republic of Ireland)


• Bayer AG (Germany)


• Bristol-Myers Squibb Company (US)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Henry Schein, Inc (US)


• Pfizer Inc. (US)

Whipple’s Disease Market Segmentation    

The Whipple’s disease market is segmented on the basis of diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others. Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others. Blood tests sub-segmented into Complete blood count (CBC), Red Blood Cell Count (RBC), serum albumin test, total protein test, and others.

On the basis of treatments, the whipple’s disease market is segmented into medications, supplements, and others. Medications is sub-segmented into Intravenous (IV) ceftriaxone (Rocephin), Intravenous (IV) penicillin, sulfamethoxazole-trimethoprim, SMX-TMP, oxycycline (Vibramycin), hydroxychloroquine (Plaquenil), and others. Supplements include vitamin supplements, mineral supplements, and others.

On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.

Regional Analysis of the Whipple’s Disease Market      

The Americas holds the largest share in the Whipple’s disease market. North American region, especially, the US dominates the market in this region. It is a rare disease and found in around less than one in million people in US. Some other factors such as advanced medical facilities, ongoing research and clinical trials, and availability of skilled health professionals. 

Increasing awareness about this disease in Latin America drives whipple’s disease market growth in this region.

The new cases of this disease is increasing in Europe. Availability of advanced diagnostic and therapeutic options, high awareness among the European population, and availability of skilled medical professional drive the European market. Availability of cost-effective of treatment in East European countries, for instance,  Poland than the other parts of the region add fuel to the growing demand. 

Owing to availability of cost-effective treatment, patients from Western European countries and Russia travel to East and Central European countries to treat this disease.

Asia Pacific region shows low prevalence of the disease. Increasing awareness about this disease in the Asian population leads the whipple’s disease market growth. The rapidly developing healthcare sector is another major driver of the whipple’s disease market. Due to rapid economic growth, rising middle class population, and their spending on healthcare and related services add fuel to the growth of whipple’s disease market.

Owing to lack of awareness about the disease, slow healthcare infrastructure development, and limited access to required medical facilities, the Middle East & Africa market is growing slower as compared to the global average. On the other hand, due to developed healthcare facilities and government support to improve public health, the Middle East countries such as the UAE dominates market of this region.

Intended Audience

• Whipple’s Disease Diagnostic and Treatment Supplies Companies


• Whipple’s Disease Diagnostic and Treatment Supplies Providers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors